wmm, Author at Invivoscribe

About wmm

This author has not yet filled in any details.
So far wmm has created 22 blog entries.

Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine

wmm2022-05-09T17:27:05+00:00May 9th, 2022|2022 Press Releases, Press Releases|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

wmm2022-01-06T05:38:03+00:00January 4th, 2022|2022 Publications, Featured Publications, Publications|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

wmm2022-01-08T23:37:03+00:00December 28th, 2021|2021 Publications, Publications|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

wmm2022-01-04T04:43:02+00:00December 8th, 2021|2021 Publications, Publications|

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

wmm2022-01-30T21:35:17+00:00November 5th, 2021|2021 Publications, Publications|

Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System

wmm2021-06-24T18:20:34+00:00June 24th, 2021|2021 Press Releases, Press Releases|

Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China

wmm2021-06-03T20:36:18+00:00June 3rd, 2021|2021 Press Releases, Press Releases|

Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco

wmm2021-02-26T19:10:54+00:00January 3rd, 2019|2019 Press Releases, Press Releases|

Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Software

wmm2021-02-26T19:12:40+00:00November 7th, 2017|2017 Press Releases, Press Releases|

Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.

wmm2021-02-26T19:12:46+00:00August 1st, 2017|2017 Press Releases, Press Releases|

FDA approves new combination treatment for acute myeloid leukemia

wmm2021-02-26T19:12:55+00:00April 28th, 2017|2017 Press Releases, Press Releases|

Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AML

wmm2021-02-26T19:13:02+00:00April 28th, 2017|2017 Press Releases, Press Releases|

Invivoscribe Expands Business into Solid Tumors with Assays and Services to Identify and Monitor CAR-T and TCR Immuno-Therapies

wmm2021-02-26T19:13:49+00:00March 28th, 2017|2017 Press Releases, Press Releases|

Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software

wmm2021-02-26T19:13:58+00:00February 28th, 2017|2017 Press Releases, Press Releases|

Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kits

wmm2021-02-26T19:14:04+00:00February 14th, 2017|2017 Press Releases, Press Releases|

Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kits

wmm2021-02-26T19:14:11+00:00January 31st, 2017|2017 Press Releases, Press Releases|

Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

wmm2021-02-26T19:14:23+00:00November 14th, 2016|2016 Press Releases, Press Releases|

Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Development

wmm2021-02-26T19:14:30+00:00May 31st, 2016|2016 Press Releases, Press Releases|

German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Position

wmm2021-02-26T19:14:37+00:00March 28th, 2016|2016 Press Releases, Press Releases|

Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)

wmm2021-02-26T19:14:49+00:00February 18th, 2016|2016 Press Releases, Press Releases|

Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific

wmm2021-02-26T19:15:19+00:00February 9th, 2016|2016 Press Releases, Press Releases|

Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations

wmm2021-02-26T19:16:48+00:00December 5th, 2015|Archived Press Releases, Press Releases|

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

About wmm

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing